A Phase III, Open-Label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-Line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-Sma

Protocol No

AZ-D516NC00001-TROPION-LUNG14

Staff Member

Jonathan Thompson

Phase

III

Summary

This project is being done to learn more about whether treatment with osimertinib in combination with Dato-DXd is superior to osimertinib alone for the first-time treatment of participants with EGFR mutation-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC)

Objective

Study of first-line osimertinib with or without Dato-Dxd for EGFRm locally advanced or metastatic NS

Status

OPEN TO ACCRUAL

A Phase III, Open-Label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-Line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer